Correction to: Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors
Target Oncol
.
2022 Mar;17(2):139.
doi: 10.1007/s11523-022-00877-y.
Authors
Amita Patnaik
1
,
Shirish Gadgeel
2
3
,
Kyriakos P Papadopoulos
4
,
Drew W Rasco
4
,
Naomi B Haas
5
,
Hirak Der-Torossian
6
,
Demiana Faltaos
6
7
,
Diane Potvin
6
,
Vanessa Tassell
6
,
Manal Tawashi
6
8
,
Richard Chao
6
,
Peter J O'Dwyer
5
Affiliations
1
START, 4383 Medical Drive, Suite 4026, San Antonio, TX, 78229, USA. amita.patnaik@startsa.com.
2
Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA.
3
Henry Ford Health System, Detroit, MI, USA.
4
START, 4383 Medical Drive, Suite 4026, San Antonio, TX, 78229, USA.
5
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
6
Mirati Therapeutics Inc., San Diego, CA, USA.
7
Olema Therapeutics, San Francisco, CA, USA.
8
HUYABIO International, San Diego, CA, USA.
PMID:
35380379
DOI:
10.1007/s11523-022-00877-y
No abstract available
Publication types
Published Erratum